Non-analgesic effects of opioids: Cardiovascular effects of opioids and their receptor systems

Current Pharmaceutical Design

Volumn 18, Issue 37, 2012, Pages 6090-6100

  Headrick, John P ^a   Pepe, Salvatore ^b   Peart, Jason N ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cardiovascular system; Cytoprotection; Opioid peptide; Opioid receptor

Indexed keywords

BETA ADRENERGIC RECEPTOR; ENKEPHALIN; G PROTEIN COUPLED RECEPTOR; MORPHINE; OPIATE; OPIATE RECEPTOR;

ARRHYTHMOGENESIS; CARDIOVASCULAR EFFECT; CELL PROTECTION; CHRONOTROPISM; HEART MUSCLE; HEART PROTECTION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW;

ANALGESICS, OPIOID; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LIGANDS; OPIOID PEPTIDES; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

EID: 84873980656     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803582360     Document Type: Review

References (194)

1. Romano MA, Seymour EM, Berry JA, McNish RA, Bolling SF. Relative contribution of endogenous opioids to myocardial ischemic tolerance. J Surg Res 2004; 118: 32-7.
2. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning and morphine-induced cardioprotection involve the d-opioid receptor in the intact rat heart. J Mol Cell Cardiol 1997; 29: 2187-95.
3. Schulz R, Gres P, Heusch G. Role of endogenous opioids in ischemic preconditioning but not in short-term hibernation in pigs. Am J Physiol Heart Circ Physiol 2001; 280: H2175-81.
4. Jang Y, Xi J, Wang H, Mueller RA, Norfleet EA, Xu Z. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 2008; 108: 243-50.
5. Zatta AJ, Kin H, Yoshishige D, et al. Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation. Am J Physiol Heart Circ Physiol 2008; 294: H1444-51.
6. Dickson EW, Hogrefe CP, Ludwig PS, Ackermann LW, Stoll LL, Denning GM. Exercise enhances myocardial ischemic tolerance via an opioid receptor-dependent mechanism. Am J Physiol Heart Circ Physiol 2008; 294: H402-8.
7. Galvão TF, Matos KC, Brum PC, Negrão CE, Luz PL, Chagas AC. Cardioprotection conferred by exercise training is blunted by blockade of the opioid system. Clinics (Sao Paulo) 2011; 66: 151-7.
8. Feuerstein G, Sirén AL. Hypothalamic mu-opioid receptors in cardiovascular control: a review. Peptides 1988; 9: 75-8.
9. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci 1988; 11: 308-14.
10. May CN, Dashwood MR, Whitehead CJ, Mathias CJ. Differential cardiovascular and respiratory responses to central administration of selective opioid agonists in conscious rabbits: correlation with receptor distribution. Br J Pharmacol 1989; 98: 903-13.
11. Barron BA. Cardiac opioids. Proc Soc Exp Biol Med 2000; 224: 1-7.
12. Head BP, Patel HH, Roth DM, et al. G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes. J Biol Chem 2005; 280: 31036-44.
13. Krumins SA, Faden AI, Feuerstein G. Opiate binding in rat hearts: modulation of binding after hemorrhagic shock. Biochem Biophys Res Commun 1985; 127: 120-8.
14. Ventura C, Bastagli L, Bernardi P, Caldera CM, Guarnieri C. Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. Biochim Biophys Acta 1989; 987: 69-74.
15. Bolte C, Newman G, Schultz Jel J. Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac kappa-opioid receptor stimulation. Am J Physiol Heart Circ Physiol 2009; 296: H967-75.
16. Saeed RW, Stefano GB, Murga JD, et al. Expression of functional delta opioid receptors in vascular smooth muscle. Int J Mol Med 2000; 6: 673-7.
17. Wittert G, Hope P, Pyle D. Tissue distribution of opioid gene expression in the rat. Biochem Biophys Res Commun 1996; 218: 877-88.
18. Weil J, Zolk O, Griepentrog J, Wenzel U, Zimmermann WH, Eschenhagen T. Alterations of the preproenkephalin system in cardiac hypertrophy and its role in atrioventricular conduction. Cardiovasc Res 2006; 69: 412-22.
19. Deo SH, Barlow MA, Gonzalez L, Yoshishige D, Caffrey JL. Cholinergic location of delta-opioid receptors in canine atria and SA node. Am J Physiol Heart Circ Physiol 2008; 294: H829-38.
20. Zimlichman R, Gefel D, Eliahou H, et al. Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats. Circulation 1996; 93: 1020-5.
21. Barron BA, Gu H, Gaugl JF, Caffrey JL. Screening for opioids in dog heart. J Mol Cell Cardiol 1992; 24: 67-77.
22. Caffrey JL, Boluyt MO, Younes A, et al. Aging, cardiac proenkephalin mRNA and enkephalin peptides in the Fisher 344 rat. J Mol Cell Cardiol 1994; 26: 701-11.
23. Howells RD, Kilpatrick DL, Bailey LC, Noe M, Udenfriend S. Proenkephalin mRNA in rat heart. Proc Natl Acad Sci USA 1986; 83: 1960-3.
24. Low KG, Allen RG, Melner MH. Association of proenkephalin transcripts with polyribosomes in the heart. Mol Endocrinol 1990; 4: 1408-15.
25. Younès A, Pepe S, Barron BA, Spurgeon HA, Lakatta EG, Caffrey JL. Cardiac synthesis, processing, and coronary release of enkephalin-related peptides. Am J Physiol Heart Circ Physiol 2000; 279: H1989-98.
26. Boluyt MO, Younes A, Caffrey JL, et al. Age-associated increase in rat cardiac opioid production. Am J Physiol 1993; 265: H212-8.
27. Mougin C, Baulay A, Henriet MT, et al. Assessment of plasma opioid peptides, beta-endorphin and met-enkephalin, at the end of an international nordic ski race. Eur J Appl Physiol Occup Physiol 1987; 56: 281-6.
28. Howlett TA, Tomlin S, Ngahfoong L, et al. Release of beta endorphin and met-enkephalin during exercise in normal women: response to training. Br Med J (Clin Res Ed) 1984; 288: 1950-2.
29. Falcone C, Guasti L, Ochan M, et al. Beta-endorphins during coronary angioplasty in patients with silent or symptomatic myocardial ischemia. J Am Coll Cardiol 1993; 22: 1614-20.
30. Jackson KE, Farias M, Stanfill AS, Caffrey JL. Transient arterial occlusion raises enkephalin in the canine sinoatrial node and improves vagal bradycardia. Auton Neurosci 2001; 94: 84-92.
31. Younes A, Pepe S, Yoshishige D, Caffrey JL, Lakatta EG. Ischemic preconditioning increases the bioavailability of cardiac enkephalins. Am J Physiol 2005; 289: H1652-61.
32. Barron BA, Oakford LX, Gaugl JF, Caffrey JL. Met-enkephalinarg-phe immunoreactivity in heart tissue. Peptides 1995; 16: 1221-1227.
33. Springhorn JP, Claycomb WC. Translation of heart preproenkephalin mRNA and secretion of enkephalin peptides from cultured cardiac myocytes. Am J Physiol 1992; 263: H1560-6.
34. Holaday JW. Cardiovascular effects of endogenous opiate systems. Annu Rev Pharmacol Toxicol 1983; 23: 541-94.
35. Pepe S, van den Brink OW, Lakatta EG, Xiao RP. Cross-talk of opioid peptide receptor and beta-adrenergic receptor signaling in the heart. Cardiovasc Res 2004; 63: 414-22.
36. van den Brink OW, Delbridge LM, Rosenfeldt FL, et al. Endogenous cardiac opioids: Enkephalins in adaptation and protection of the heart. Heart Lung Circ 2003; 12: 178-87.
37. Xiao RP, Pepe S, Spurgeon HA, Capogrossi MC, Lakatta EG. Opioid peptide receptor stimulation reverses OO-adrenergic effects in rat heart cells. Am J Physiol 1997; 272: H797-805.
38. Schultz JE, Hsu AK, Nagase H, Gross GJ. Tan-67 a d1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and Katp channels. Am J Physiol 1998; 274: H909-14.
39. Shultz JE, Hsu AK, Gross GL. Ischemic preconditioning in the intact rat heart is mediated by d1 but not m or k-opioid receptors. Circulation 1998; 97: 1282-9.
40. Schultz JE, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995; 268: H2157-61.
41. Peart JN, Gross ER, Gross GJ. Effect of exogenous kappa opioid receptor activation in rat model of myocardial infarction. J Cardiovasc Pharmacol 2004; 43: 410-5.
42. Pepe S, Xiao RP, Hohl C, Altschuld R, Lakatta EG. 'Cross talk' between opioid peptide and adrenergic receptor signaling in isolated rat heart. Circulation 1997; 95: 2122-9.
43. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase b inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94: 960-6.
44. Farias M, Jackson K, Yoshishige D, Caffrey JL. Bimodal [-opioid receptors regulate vagal bradycardia in canine sinoatrial node. Am J Physiol 2003; 285: H1332-9.
45. Farias M, Jackson KE, Yoshishige D, Caffrey JL. Cardiac enkephalins interrupt vagal bradycardia via d2-opioid receptors in sinoatrial node. Am J Physiol 2003; 284: H1693-701.
46. Jackson KE, Farias M, Stanfill A, Caffrey JL. Delta opioid receptors inhibit vagal bradycardia in the sinoatrial node. J Cardiovasc Pharmacol Therapeut 2001; 6: 385-93.
47. Huang MH, Friend DS, Sunday ME, et al. An intrinsic adrenergic system in mammalian heart. J Clin Invest 1996; 98: 1298-303.
48. Huang MH, Bahl JJ, Wu Y, Larson DL, Hu FL, Ewy GA. Neuroendocrine properties of intrinsic cardiac adrenergic cells in fetal rat heart. Am J Physiol 2005; 288: H497-503.
49. Huang MH, Wang HQ, Roeske WR, et al. Mediating delta-opioidinitiated heart protection via the beta2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell. Am J Physiol 2007; 293: H376-84.
50. Huang MH, Nguyen V, Wu Y, et al. Reducing ischaemia/reperfusion injury through delta-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signaling. Cardiovasc Res 2009; 84: 452-60.
51. Kosterlitz HW, Taylor DW. The effect of morphine on vagal inhibition of the heart. Br J Pharmacol Chemother 1959; 14: 209-14.
52. Pur-Shahriari AA, Mills RA, Hoppin FG, Dexter L. Comparison of chronic and acute effects of morphine sulfate on cardiovascular function. Am J Cardiol 1967; 20: 654-59.
53. Hotvedt R, Refsum H. Cardiac effects of thoracic epidural morphine caused by increased vagal activity in the dog. Acta Anaesthesiol. Scand 1986; 30: 76-83.
54. Randich A, Thurston CL, Ludwig PS, Robertson JD, Rasmussen C. Intravenous morphine-induced activation of vagal afferents: peripheral, spinal and CNS substrates mediating inhibition of spinal nociception and cardiovascular responses. J Neurophysiol 1992; 68: 1027-45.
55. Caffrey JL, Mateo Z, Napier LD, Gaugl JF, Barron BA. Intrinsic cardiac enkephalins inhibit vagal bradycardia in the dog. Am J Physiol 1995; 268: H848-55.
56. Weitzell R, Illes P, Starke K. Inhibition via opioid μ-and β-receptors of vagal transmission in rabbit isolated heart. Naunyn Schmiedebergs Arch Pharmacol 1984; 328: 186-90.
57. Kennedy BL, West TC. Effect of morphine on electrically-induced release of autonomic mediators in the rabbit sinoatrial node. J Pharmacol Exp Ther 1967; 157: 149-58.
58. Caffrey JL. Enkephalin inhibits vagal control of heart rate, contractile force and coronary blood flow in the canine heart in vivo. Journal of the Autonomic Nervous System 1999; 76: 75-82.
59. Musha T, Satoh E, Koyanagawa H, Kimura T, Satoh S. Effect of opioid agonists on sympathetic and parasympathetic transmission to dog heart. J Pharmacol Exp Ther 1989; 250: 1087-91.
60. Barlow MA, Deo S, Johnson S, Caffrey JL. Vagotonic effects of enkephalin are not mediated by sympatholytic mechanisms. Exp Biol Med (Maywood) 2006; 231: 387-95.
61. Gu H, Gaugl JF, Barron BA, Caffrey JL. Dynorphin, naloxone, and overflow of norepinephrine during cardiac nerve stimulation in dogs. Am J Physiol 1992; 263: H153-61.
62. Canossa M, Ventura C, Vaona I, Carboni L, Guarnieri C, Spampinato S. Prodynorphin mRNA expression in adult cultured rat ventricular cardiac myocytes. Biochim Biophys Acta 1993; 172: 247-50.
63. Ventura C, Guarnier C, Vaona I, Campana G, Pintus G, Spampinato S. Dynorphin gene expression and release in the myocardial cell. J Biol Chem 1994; 269: 5384-6.
64. Stanfill A, Jackson KE, Farias M, et al. Leucine-enkephalin interrupts sympathetically mediated tachycardia prejunctionally in the canine sinoatrial node. Proc Soc Exp Biol Med 2003; 228: 898-906.
65. Wu C, Fry CH, Henry J. The mode of action of several opioids on cardiac muscle. Exp Physiol 1997; 82: 261-72.
66. Ventura C, Spurgeon H, Lakatta EG, Guarnieri C, Capogrossi MC. Kappa and delta opioid receptor stimulation affects cardiac myocyte function and Ca2+ release from an intracellular pool in myocytes and neurons. Circ Res 1992; 70: 66-81.
67. Hanouz JL, Yvon A, Guesne G, et al. The in vitro effects of remifentanil, sufentanil, fentanyl, and alfentanil on isolated human right atria. Anesth Analg 2001; 93: 543-9.
68. Kanaya N, Zakhary DR, Murray PA, Damron DS. Differential effects of fentanyl and morphine on intracellular Ca2+ transients and contraction in rat ventricular myocytes. Anesthesiology 1998; 89: 1532-42.
69. Llobell F, Laorden ML. Characterization of the opioid receptor subtypes mediating the negative inotropic effects of DAMGO, DPDPE and U-50, 488H in isolated human right atria strips. Neuropeptides 1995; 29: 115-9.
70. Huang MH, Nguyen V, Wu Y, et al. Reducing ischaemia/reperfusion injury through delta-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signaling. Cardiovasc Res 2009; 84: 452-60.
71. Omoniyi AT, Kett A, Wu D, Soong Y, Clapp JF 3rd, Szeto HH. A peripheral site of action for the attenuation of baroflex-mediated bradycardia by intravenous mu-opioid agonists. J Cardiovasc Pharmacol 2000; 35: 269-74.
72. Maslov LN, Barzakh EI, Platonov AA, Minin SM, Ovchinnikov MV. Chronotropic effect of D-Ala2, Leu5, Arg6-enkephalin (dalargin) is associated with activation of peripheral kappa-opioid receptors. Bull Exp Biol Med 2005; 140: 682-6.
73. Maslov LN, Lishmanov YB, Barzakh EI, Lasukova TV, Rice KK, Oeltgen PR. Negative inotropic and chronotropic effects of deltaopioid receptor antagonists are mediated via non-opioid receptors. Bull Exp Biol Med 2006; 141: 420-3.
74. Zaballos M, Jimeno C, Almendral J, et al. Cardiac electrophysiological effects of remifentanil: study in a closed-chest porcine model. Br J Anaesth 2009; 103: 191-8.
75. Andrews CM, Krantz MJ, Wedam EF, Marcuson MJ, Capacchione JF, Haigney MC. Methadone-induced mortality in the treatment of chronic pain: role of QT prolongation. Cardiol J 2009; 16: 210-7.
76. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137: 501-4.
77. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 2006; 316: 1098-106.
78. Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 2002; 303: 688-94.
79. Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf 2007; 6: 289-303.
80. DeSilva RA, Vemer RL, Lown B. Protective effect of the vagotonic action of morphine sulphate on ventricular vulnerability. Cardiovasc Res 1978; 12: 167-72.
81. Laubie M, Schmitt H, Canellas I, Roquebert J, Demichel P. Centrally mediated bradycardia and hypotension induced by narcotic analgesics: dextromoramide and fentanyl. Eur J Pharmacol 1974; 28: 66-75.
82. Laubie M, Schmitt H, Drouillat M. Central sites and mechanisms of the hypotensive and bradycardic effects of the narcotic analgesic agent fentanyl. Naunyn Schmiedebergs Arch Pharmacol 1977: 296: 255-61.
83. Saini V, Carr DB, Hagestad EL, Lown B, Verrier RL. Antifibrillatory mechanism of the narcotic agonist fentanyl. Am Heart J 1988: 115: 598-605.
84. Caffrey JL, Wooldridge CB, Gaugl JF. The interaction of endogenous opiates with autonomic circulatory control in the dog. Circ Shock 1985; 17: 233-42.
85. Giles TD, Sander GE. Interactions of leucine-enkephalin with alpha adrenoreceptors in the conscious dog. Chest 1983; 83S: 364S-6S.
86. Yu X, Zhang W, Bian J, Wong TM. Pro-and anti-arrhythmic effects of a kappa opioid receptor agonist: a model for the biphasic action of a local hormone in the heart. Clin Exp Pharmacol Physiol 1999; 26: 842-4.
87. Bian JS, Pei JM, Cheung CS, Zhang WM, Wong TM. kappa-opioid receptor stimulation induces arrhythmia in the isolated rat heart via the protein kinase C/Na(+)-H(+)exchange pathway. J Mol Cell Cardiol 2000; 32: 1415-27.
88. Xiao G-S, Zhou J-J, Cheung Y-F, Lic G-R, Wong TM. Effects of U50,488H on transient outward and ultra-rapid delayed rectifier K+ currents in young human atrial myocytes. Eur J Pharmacol 2003; 473: 97-103.
89. Afshari R, Maxwell SR, Webb DJ, Bateman DN. Morphine is an arteriolar vasodilator in man. Br J Clin Pharmacol 2009; 67: 386-93.
90. Gursoy S, Bagcivan I, Yildirim MK, Berkan O, Kaya T. Vasorelaxant effect of opioid analgesics on the isolated human radial artery. Eur J Anaesthesiol 2006; 23: 496-500.
91. Sahin AS, Duman A, Atalik EK, et al. The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth 2005; 19: 197-200.
92. Hu ZY, Lin PT, Liu J, Liao DQ. Remifentanil induces L-type Ca2+ channel inhibition in human mesenteric arterial smooth muscle cells. Can J Anaesth 2008; 55: 238-44.
93. Raimundo JM, Sudo RT, Pontes LB, Antunes F, Trachez MM, Zapata-Sudo G. In vitro and in vivo vasodilator activity of racemic tramadol and its enantiomers in Wistar rats. Eur J Pharmacol 2006; 530: 117-23.
94. Sahin N, Ozdem S, Sadan G. The effect of nitric oxide synthase blockade on responses to morphine in rat aortic rings. Auton Autacoid Pharmacol 2002; 22: 103-7.
95. Wang CL, Yu Y, Lai LH, Cui Y, Wang X, Wang R. Cardiovascular responses to intrathecal administration of endomorphins in anesthetized rats. Peptides 2007; 28: 871-7.
96. Rao SP, Conley A, Dunbar JC. Cardiovascular responses to central administration of mu and kappa opioid receptor agonist and antagonist in normal rats. Peptides 2003; 24: 745-54.
97. Murry CE, Jennings R, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
98. Kharbanda RK. Cardiac conditioning: a review of evolving strategies to reduce ischaemia-reperfusion injury. Heart 2010; 96: 1179-86.
99. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579-88.
100. Na HS, Kim YI, Yoon YW, Han HC, Nahm SH, Hong SK. Ventricular premature beat-driven intermittent restoration of coronary blood flow reduces the incidence of reperfusion-induced ventricular fibrillation in a cat model of regional ischemia. Am Heart J 1996; 132: 78-83.
101. Yang XC, Liu Y, Wang LF, et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol 2007; 19: 424-30.
102. Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamidesensitive mechanism in the rat heart. Circ Res 1996; 78: 1100-4.
103. Fryer RM, Hsu AK, Eells JT, Nagase H, Gross GJ. Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res 1999; 84: 846-51.
104. Dickson EW, Blehar DJ, Carraway RE, Heard SO, Steinberg G, Przyklenk K. Naloxone blocks transferred preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 2001; 33: 1751-6.
105. Wu S, Li HY, Wong TM. Cardioprotection of preconditioning by metabolic inhibition in the rat ventricular myocyte. Involvement of kappa-opioid receptor. Circ Res 1999; 84: 1388-95.
106. Wang GY, Wu S, Pei JM, Yu XC, Wong TM. Kappa-but not delta-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats. Am J Physiol Heart Circ Physiol 2001; 280: H384-91.
107. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 2009; 204: 334-41.
108. Wong GT, Li R, Jiang LL, Irwin MG. Remifentanil postconditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand 2010, 54, 510-8.
109. Guo H, Zhang R, Zhang Y, et al. Endogenous-Opioid Peptide Mediates the Cardioprotection Induced by Ischemic Postconditioning. J Cardiovasc Pharmacol. 2011 Jun 7. [Epub ahead of print].
110. Gross ER, Hsu AK, Gross GJ. GSK3beta inhibition and K(ATP) channel opening mediate acute opioid-induced cardioprotection at reperfusion. Basic Res Cardiol 2007; 102: 341-9.
111. Peart JN, Gross ER, Reichelt ME, Hsu A, Headrick JP, Gross GJ. Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts. Basic Res Cardiol 2008; 103: 454-63.
112. Gross ER, Hsu AK, Gross GJ. Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg 2009; 109: 1395-402.
113. Tong G, Sun Z, Wei X, et al. U50,488H postconditioning reduces apoptosis after myocardial ischemia and reperfusion. Life Sci 2011; 88: 31-8.
114. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448-60.
115. Huhn R, Heinen A, Weber NC, Schlack W, Preckel B, Hollmann MW. Ischaemic and morphine-induced post-conditioning: impact of mK(Ca) channels. Br J Anaesth 2010; 105: 589-95.
116. Lecour, S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47: 32-40.
117. You L, Li L, Xu Q, Ren J, Zhang F. Postconditioning reduces infarct size and cardiac myocyte apoptosis via the opioid receptor and JAK-STAT signaling pathway. Mol Biol Rep 2011; 38: 437-43.
118. Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating RISK: a role for JAK-STAT signaling in postconditioning? Am J Physiol Heart Circ Physiol 2008; 295: H1649-56.
119. Gross GJ. Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol 2003; 35: 709-18.
120. Peart JN, Gross ER, Gross GJ. Opioid-induced preconditioning: Recent advances and future perspectives. Vascular Pharmacology 2005; 42: 211-8.
121. Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: From adenosine receptor to K-ATP channel. Ann Rev Physiol 2000; 62: 79-109.
122. Fryer RM, Wang Y, Hsu AK, Gross GJ. Essential activation of PKC-delta in opioid-initiated cardioprotection. Am J Physiol 2001; 280: H1346-53.
123. ATP channel triggers opioid-induced delayed cardioprotection in the rat. Circ Res 2002; 91: 186-8.
124. Peart JN, Gross GJ. Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. Am J Physiol Heart Circ Physiol 2003; 285: H81-9.
125. Xi J, Tian W, Zhang L, Jin Y, Xu Z. Morphine prevents the mitochondrial permeability transition pore opening through NO/cGMP/PKG/Zn2+/GSK-3beta signal pathway in cardiomyocytes. Am J Physiol Heart Circ Physiol 2010; 298: H601-7.
126. ATP channels, free radicals and MEK1/2. J Mol Cell Cardiol 2003; 35: 985-92.
127. ATP channel triggers delayed ischemic preconditioning in rats. Am J Physiol Heart Circ Physiol 2005; 288: H445-7.
128. Lee JW, Joshi S, Chan JSC, Wong, YH. Differential coupling of m-,-, and k-opioid receptors to G--16-mediated stimulation of phospholipase C. J Neurochem 1998; 70: 2203-11.
129. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther 2001; 89: 123-3.
130. Fryer RM, Schultz JE, Gross GJ. Pretreatment with tyrosine kinase inhibitors partially attenuates ischemic preconditioning in rat hearts. Am J Physiol 1998; 275: H2009-15.
131. Gross RA, Moises HC, Uhler MD, Macdonald RL. Dynorphin A and cAMP-dependent protein kinase independently regulate neuronal calcium currents. Proc Natl Acad Sci USA 1990; 87: 7025-9.
132. North RA, Williams JT, Surprenant A, Christie MJ. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci USA 1987; 84: 5487-91.
133. Frässdorf J, Huhn R, Niersmann C, et al. Morphine induces preconditioning via activation of mitochondrial K(Ca) channels. Can J Anaesth 2010; 57: 767-73.
134. Maslov LN, Lishmanov YB, Oeltgen PR, et al. Activation of peripheral delta2 opioid receptors increases cardiac tolerance to ischemia/reperfusion injury Involvement of protein kinase C, NOsynthase, KATP channels and the autonomic nervous system. Life Sci 2009; 84: 657-63.
135. Fryer RM, Wang Y, Hsu AK, Nagase H, Gross GJ. Dependence of 1-opioid receptor-induced cardioprotection on a tyrosine kinasedependent but not a Src-dependent pathway. J Pharmacol Exp Ther 2001; 299: 477-82.
136. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009; 104: 1240-52.
137. Förster K, Richter H, Alexeyev MF, Rosskopf D, Felix SB, Krieg T. Inhibition of glycogen synthase kinase 3beta prevents peroxideinduced collapse of mitochondrial membrane potential in rat ventricular myocytes. Clin Exp Pharmacol Physiol 2010; 37: 684-8.
138. Horikawa YT, Patel HH, Tsutsumi YM, et al. Caveolin-3 expression and caveolae are required for isofluorane-induced cardiac protection from hypoxia and ischemia/reperfusion injury. J Mol Cell Cardiol 2008; 44: 123-30.
139. Tsutsumi YM, Horikawa YT, Jennings MM, et al. Cardiac-specific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation 2008; 118: 1979-88.
140. Patel HH, Head BP, Petersen HN, et al. Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and delta-opioid receptors. Am J Physiol Heart Circ Physiol 2006; 291: H344-50.
141. Tsutsumi YM, Kawaraguchi Y, Niesman IR, Patel HH, Roth DM. Opioid-induced preconditioning is dependent on caveolin-3 expression. Anesth Analg 2010; 111: 1117-21.
142. Kim HS, Cho JE, Hwang KC, Shim YH, Lee JH, Kwak YL. Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival. Eur J Pharmacol 2010; 628: 132-9.
143. Wenzlaff H, Stein B, Teschemacher H. Diminution of contractile response by kappa-opioid receptor agonists in isolated rat ventricular cardiomyocytes is mediated via a pertussis toxin-sensitive G protein. Nauyn-Schmiederberg's Arch Pharmacol 1998; 358: 360-6.
144. 2+ pathway in the cardiac k-opioid receptor. Am J Physiol 1998; 274: C82-7.
145. Wong TM, Wu S. Roles of kappa opioid receptors in cardioprotection against ischemia: the signaling mechanisms. Sheng Li Xue Bao 2003; 55, 115-20.
146. Patel HH, Moore J, Hsu AK, Gross GJ. Cardioprotection at a distance: mesenteric artery occlusion protects the myocardium via an opioid sensitive mechanism. J Mol Cell Cardiol 2002; 34: 1317-23.
147. Dickson EW, Tubbs RJ, Porcaro WA, et al. Myocardial preconditioning factors evoke mesenteric ischemic tolerance via opioid receptors and K(ATP) channels. Am J Physiol Heart Circ Physiol 2002; 283: H22-8.
148. Zhang SZ, Wang NF, Xu J, et al. Kappa-opioid receptors mediate cardioprotection by remote preconditioning. Anesthesiology 2006; 105: 550-6.
149. Rentoukas I, Giannopoulos G, Kaoukis A, et al. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv 2010; 3: 49-55.
150. Lim SY, Yellon DM, Hausenloy DJ. The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol 2010; 105: 651-5.
151. Li R, Wong GT, Wong TM, Zhang Y, Xia Z, Irwin MG. Intrathecal morphine preconditioning induces cardioprotection via activation of delta, kappa, and mu opioid receptors in rats. Anesth Analg 2009; 108: 23-9.
152. Wong GT, Ling Ling J, Irwin MG. Activation of central opioid receptors induces cardioprotection against ischemia-reperfusion injury. Anesth Analg 2010; 111: 24-8.
153. Zhang Y, Irwin MG, Lu Y, et al. Intracerebroventricular administration of morphine confers remote cardioprotection-Role of opioid receptors and calmodulin. Eur J Pharmacol 2011; 656: 74-80.
154. Yao L, Wong GT, Xia Z, Irwin MG. Interaction between spinal opioid and adenosine receptors in remote cardiac preconditioning: effect of intrathecal morphine. J Cardiothorac Vasc Anesth 2011; 25: 444-8.
155. Peart JN, Gross GJ. Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways. Am J Physiol Heart Circ Physiol 2006; 291: H1746-53.
156. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, Devi LA. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 2001; 98: 343-8.
157. Peart JN, Gross GJ. Cardioprotection following adenosine kinase inhibition in rat hearts. Basic Res Cardiol 2005; 100: 328-36.
158. Williams-Pritchard GA, Peart JN, Headrick JP. Transcriptional and Cell Signaling Cross-Talk between Adenosine and Diploid Receptors in Cardiac Cells. Circulation 2008; 118: S293-3.
159. Williams-Pritchard G, Knight M, Hoe LS, Headrick JP, Peart JN. Essential role of EGFR in cardioprotection and signaling responses to A1 adenosine receptors and ischemic preconditioning. Am J Physiol Heart Circ Physiol 2011; 300: H2161-8.
160. Förster K, Kuno A, Solenkova N, Felix SB, Krieg T. The deltaopioid receptor agonist DADLE at reperfusion protects the heart through activation of pro-survival kinases via EGF receptor transactivation. Am J Physiol Heart Circ Physiol 2007; 293: H1604-8.
161. Peart JN, Gross GJ. Morphine-tolerant mice exhibit a profound and persistent cardioprotective phenotype. Circulation 2004; 109: 1219-22.
162. Peart JN, See Hoe LE, Gross GJ, Headrick JP. Sustained ligandactivated preconditioning via β-opioid receptors. J Pharmacol Exp Ther 2011; 336: 274-81.
163. Peart JN, Headrick JP. Sustained cardioprotection: Exploring unconventional modalities. Vascular Pharmacology 2008; 49: 63-70.
164. Peart JN, Gross ER, Headrick JP, Gross GJ. Impaired p38 MAPK/HSP27 signaling underlies aging-related failure in opioidmediated cardioprotection. J Mol Cell Cardiol 2007; 42: 972-80.
165. Peart JN, Gross GJ. Chronic exposure to morphine produces a marked cardioprotective phenotype in aged mouse hearts. Exp Gerontol 2004; 39: 1021-6.
166. Cheng L, Ma S, Wei LX, et al. Cardioprotective and antiarrhythmic effect of U50,488H in ischemia/reperfusion rat heart. Heart Vessels 2007; 22: 335-44.
167. Jin-Cheng L, Wen Y, Zhao Y, et al. Anti-arrhythmic effects of kappa-opioid receptor and its changes in ischemia and reperfusion. Arch Med Res 2008; 39: 483-8.
168. Zhang QY, Wang W, Shi QX, et al. Antiarrhythmic effect mediated by δ-opioid receptor is associated with Cx43 stabilization. Crit Care Med 2010; 38: 2365-76.
169. Pugsley MK, Saint DA, Penz MP, Walker MJ. Electrophysiological and antiarrhythmic actions of the kappa agonist PD 129290, and its R, R (+)-enantiomer, PD 129289. Br J Pharmacol 1993; 110: 1579-85.
170. Pugsley MK, Saint DA, Hayes ES, Kramer D, Walker MJ. Sodium channel-blocking properties of spiradoline, a kappa receptor agonist, are responsible for its antiarrhythmic action in the rat. J Cardiovasc Pharmacol 1998; 32: 863-74.
171. Pugsley MK, Penz WP, Walker MJ, Wong TM. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade. Br J Pharmacol 1992; 105: 521-6.
172. Sheng JZ, Wong NS, Wang HX, Wong TM. Pertussis toxin, but not tyrosine kinase inhibitors, abolishes effects of U-50488H on [Ca2+]i in myocytes. Am J Physiol 1997; 272: C560-4.
173. Bian JS, Zhang WM, Xia Q, Wong TM. Phospholipase C inhibitors attenuate arrhythmias induced by kappa-receptor stimulation in the isolated rat heart. J Mol Cell Cardiol 1998; 30: 2103-10.
174. Zhang WM, Wang HX, Xia Q, Wong TM. Inhibition of [3H]-U69593 binding and the cardiac effects of U50, 488H by calcium channel blockers in the rat heart. Br J Pharmacol 1997; 120: 827-32.
175. Hung CF, Wu MH, Tsai CH, Chu SH, Chi JF, Su MJ. Electrophysiological mechanisms for the antiarrhythmic activities of naloxone on cardiac tissues. Life Sci 1998; 63: 1205-19.
176. Kuo JS, Wu JP, Tsai PJ, Yang CS. Ferrous ion diminished the antiarrhythmic effect of naloxone in myocardial ischemia of isolated rat hearts. Biol Pharm Bull 1998; 21: 710-2.
177. Stein M, Noorman M, van Veen TA, et al. Dominant arrhythmia vulnerability of the right ventricle in senescent mice. Heart Rhythm 2008; 5: 438-48.
178. Stein M, Boulaksil M, Jansen JA, et al. Reduction of fibrosisrelated arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. Am J Physiol Heart Circ Physiol 2010; 299: H310-21.
179. Wu W, Lu Z. Loss of anti-arrhythmic effect of vagal nerve stimulation on ischemia-induced ventricular tachyarrhythmia in aged rats. Tohoku J Exp Med 2011; 223: 27-33.
180. Boulaksil M, Winckels SK, Engelen MA, et al. Heterogeneous Connexin43 distribution in heart failure is associated with dispersed conduction and enhanced susceptibility to ventricular arrhythmias. Eur J Heart Fail 2010; 12: 913-21.
181. Miura T, Yano T, Naitoh K, et al. Delta-opioid receptor activation before ischemia reduces gap junction permeability in ischemic myocardium by PKC-epsilon-mediated phosphorylation of connexin 43. Am J Physiol Heart Circ Physiol 2007; 293: H1425-31.
182. Yin W, Zhang P, Huang JH, et al. Stimulation of kappa-opioid receptor reduces isoprenaline-induced cardiac hypertrophy and fibrosis. Eur J Pharmacol 2009; 607: 135-42.
183. Wu G, Wang H, Yang J, et al. kappa-Opioid receptor stimulation inhibits augmentation of Ca(2+) transient and hypertrophy induced by isoprenaline in neonatal rat ventricular myocytes-Role of CaMKIIdelta(B). Eur J Pharmacol 2008; 595: 52-7.
184. Jaiswal A, Kumar S, Seth S, Dinda AK, Maulik SK. Effect of U50,488H, a δ-opioid receptor agonist on myocardial α-and β-myosin heavy chain expression and oxidative stress associated with isoproterenol-induced cardiac hypertrophy in rat. Mol Cell Biochem 2010; 345: 231-40.
185. Bolte C, Newman G, Schultz Jel J. Kappa and delta opioid receptor signaling is augmented in the failing heart. J Mol Cell Cardiol 2009; 47: 493-503.
186. Ebrahimi F, Tavakoli S, Hajrasouliha AR, et al. Involvement of endogenous opioid peptides and nitric oxide in the blunted chronotropic and inotropic responses to beta-adrenergic stimulation in cirrhotic rats. Fundam Clin Pharmacol 2006; 20: 461-71.
187. Gaskari SA, Mani AR, Ejtemaei-Mehr S, et al. Do endogenous opioids contribute to the bradycardia of rats with obstructive cholestasis? Fundam Clin Pharmacol 2002; 16: 273-9.
188. Nahavandi A, Dehpour AR, Mani AR, Homayounfar H, Abdoli A, Abdolhoseini MR. The role of nitric oxide in bradycardia of rats with obstructive cholestasis. Eur J Pharmacol 2001; 411: 135-141.
189. Wong SC, Ingenito AJ. Possible opioid receptor function changes in isolated atria of the spontaneously hypertensive rat. Gen Pharmacol 1993; 24: 1483-90.
190. Raimundo JM, Pontes LB, Antunes F, Sudo RT, Trachez MM, Zapata-Sudo G. Comparative effects of tramadol on vascular reactivity in normotensive and spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2008; 35: 1197-203.
191. Guo HT, Zhang RH, Huang LY, et al. Mechanisms involved in the hypotensive effect of a kappa-opioid receptor agonist in hypertensive rats. Arch Med Res 2007; 38: 723-9.
192. McLaughlin PJ, Allar MA. Preproenkephalin gene expression and [Met5]-enkephalin levels in the developing rat heart. Brain Res Mol Brain Res 1998; 60: 160-7.
193. Mousa SA, Shaqura M, Schäper J, et al. Developmental expression of δ-opioid receptors during maturation of the parasympathetic, sympathetic, and sensory innervations of the neonatal heart: early targets for opioid regulation of autonomic control. J Comp Neurol 2011; 519: 957-71.
194. Penny DJ. Ischaemic preconditioning: Developing knowledge of a developing process. Heart Lung & Circulation 2003; 12: 8-10.